• Galderma flagged new clinical updates on nemolizumab in atopic dermatitis, including long-term safety and sustained benefit in an extension study.
• Results will be presented at the EADV congress in Vienna on Oct. 1, with additional analyses scheduled as e-posters.
• Separate presentations will cover nemolizumab’s longer-term profile in prurigo nodularis, emphasizing symptom relief with broader quality-of-life improvements.
• The program also includes real-world analyses on itch burden in treated patients, supporting a push to strengthen evidence beyond controlled trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galderma Group AG published the original content used to generate this news brief on September 23, 2026, and is solely responsible for the information contained therein.